PharmTech Weekly Roundup—July 31, 2026

This week on PharmTech.com, the theme of promise to practice was obvious. AI is being utilized in drug discovery, but plant-floor execution still lags behind. Regulators are modernizing rules for advanced therapies and peptides. And manufacturers are rethinking where and how they build capacity, transfer technology, and monitor quality in real time.

In news this week, GSK announced a £400 million investment to consolidate R&D at Cambridge Biomedical Campus while closing Stevenage and expanding scale-up manufacturing at Ware, reflecting a trend of placing research near academic and clinical hubs.

The FDA revised draft guidance documents for 17 generic peptide products tightening expectations for impurity testing, immunogenicity, and structural analysis ahead of a September comment deadline.

PharmTech’s industry update continues. Halfway through the year, experts agree that next-generation modalities like ADCs and GLP-1s are advancing quickly, but regulatory compliance and organizational readiness remain the industry's toughest execution hurdles.

Cheryl Barton, a contributing writer for PharmTech Europe, highlights how European biotechs are using AI-driven target discovery to push respiratory treatment beyond broad immunosuppression toward precision therapies for asthma, COPD, and pulmonary fibrosis.

CTMC's Jason Bock provided PharmTech with his take on the FDA's proposed single-registration rule for distributed “hub-and-spoke” networks. He says the rule could give personalized cell and gene therapy makers the regulatory clarity to build patient-proximate supply chains. Bock adds that earning FDA's trust under this streamlined model will require manufacturers to adopt fully digital, harmonized quality systems so deviations and corrective actions can be shared instantly across every site.

Industry experts from Kindeva, QbDVision, Mabion, and Symbiosis participated in a panel discussion on best practices for tech transfer. The panelists say successful technology transfer depends less on paperwork and more on capturing the process understanding and hands-on operational knowledge that standard batch records typically leave out. They also described how tiered governance, clear escalation paths, and regulatory planning run in parallel with execution let sponsors maintain oversight of contract manufacturers without slipping into micromanagement.

In an interview with PharmTech, Lonza's Atul Mohindra explains how fusing Raman, NIR, and other spectroscopic data with chemometric models enables real-time, automated control of nutrient feeds and quality attributes, supporting right-first-time manufacturing at scale.

And finally, in this month’s Pharma Fundamentals episode, Robert Dream, managing director of HDR Company and a PharmTech Editorial Advisory Board member, explains how validated hold times protect biopharmaceutical quality between processing steps, and why cumulative hold time across an entire process matters as much as any single pause.

From AI's execution gap to regulatory modernization and real-time process control, it’s clear that manufacturing execution must catch up with innovation. For the full stories, visit PharmTech.com.